Health & Fitness
Health and Fitness
Health and Fitness
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011 Dyax Corp. to Present at the UBS Global Specialty Pharmaceuticals Conference
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ Dyax Corp. ] (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the 2011 UBS Global Specialty Pharmaceuticals Conference, being held May 24-25 2011 at the UBS offices in London. Mr. Christensen will provide a corporate update regarding the Companya™s three major business franchises and value drivers - KALBITOR® (ecallantide), the Licensing and Funded Research Program (LFRP) and the internal pipeline, including label expansion efforts with KALBITOR. The Dyax presentation is scheduled for Tuesday, May 24 at 3:30 PM BST (10:30 AM ET).
The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at [ www.dyax.com ]. The webcast will also be available on the Dyax website for a limited period of time following the conference.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs. The Companya™s lead product, ecallantide, has been approved under the brand name KALBITOR® in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
Dyax is commercializing KALBITOR in the United States independently, and establishing strategic partnerships to develop and commercialize ecallantide for the treatment of HAE in key regions worldwide. Currently, Dyax has partnership agreements for regions including Europe, Japan, Russia, the Middle East, Israel, North Africa, Australia and New Zealand. The company is also exploring other potential indications for ecallantide, either alone or through partnerships, including drug-induced angioedema and retinal vein occlusion-induced macular edema.
Ecallantide and other compounds in Dyaxa™s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP, which has approximately 75 revenue generating licenses and collaborations for therapeutic discovery, as well as for affinity separations, diagnostic imaging, and research reagents. The success of the Companya™s LFRP royalty portfolio is illustrated by the programa™s advanced licensee pipeline that includes 17 candidates in clinical development. Of those candidates, four are in Phase 3 clinical trials, four are in Phase 2 and nine are in Phase 1.
